2019
DOI: 10.1016/s0145-2126(19)30268-1
|View full text |Cite
|
Sign up to set email alerts
|

CYP3A5*3, CYP3A4*18 and CYP2B6 gene polymorphisms in chronic myeloid leukemia patients in Azerbaijan

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…A recent study reported that CYP3A4*18 allele is significantly associated with the underdosing of imatinib mesylate (IM) therapy in patients with chronic myeloid leukemia (CML). This resistance reaction is speculated to be due to lower metabolic activity of CYP3A4.18 enzyme (Asadov et al, 2023). Combined with pharmacokinetic (PBPK) modeling, a study from Japan simulated plasma and liver exposure of atorvastatin suggested that CYP3A4*16 homozygotes exhibited higher values of the maximum concentration and area under the concentration curve than subjects carrying wild type CYP3A4*1/*1 (Adachi et al, 2023).…”
Section: Introductionmentioning
confidence: 99%
“…A recent study reported that CYP3A4*18 allele is significantly associated with the underdosing of imatinib mesylate (IM) therapy in patients with chronic myeloid leukemia (CML). This resistance reaction is speculated to be due to lower metabolic activity of CYP3A4.18 enzyme (Asadov et al, 2023). Combined with pharmacokinetic (PBPK) modeling, a study from Japan simulated plasma and liver exposure of atorvastatin suggested that CYP3A4*16 homozygotes exhibited higher values of the maximum concentration and area under the concentration curve than subjects carrying wild type CYP3A4*1/*1 (Adachi et al, 2023).…”
Section: Introductionmentioning
confidence: 99%